Early action, lifelong impact: the crucial role of early detection, risk stratification, and aggressive treatment of familial hypercholesterolaemia.

Competing Interests: Conflict of interest: W.K. reports advisory board fees from AstraZeneca, Novartis, Amgen, Pfizer, The Medicines Company, DalCor, Kowa, Corvidia, OMEICOS, Daiichi-Sankyo, Novo Nordisk, New Amsterdam Pharma, TenSixteen Bio, Esperion, Genentech; lecture fees from Bristol-Myers Squibb, Novartis, Amgen, Berlin-Chemie, Sanofi and AstraZeneca; grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work. V.S. reports lecture fees from Novartis, Daiichi-Sankyo, and Amgen. R.S.S. has no conflict of interest.